Catalyst succession in cardiology: HORIZON and ZEUS are the two most watched readouts in 3Q26

Overview

This report discusses the two key remaining phase 3 clinical catalysts in cardiovascular medicine for 3Q26 after the failure of CARDIO-TTRansform: NVS/IONS pelacarsen HORIZON and NVO ziltivekimab ZEUS. The authors argue that although investors became more cautious after the ATTR-cardiomyopathy event, these two readouts may still respectively validate whether Lp(a) lowering and inflammation lowering can reduce cardiovascular event risk, and have a knock-on effect across multiple pharmaceutical and biotechnology companies.

Core views

The central view is threefold: first, HORIZON is the first large-scale study to validate whether Lp(a) lowering can lower cardiovascular risk; if it is positive or shows at least a trend in efficacy, it would support the Lp(a) drug ecosystem, though commercialization remains constrained by screening rates, payer dynamics, and long-acting or oral competing options. Second, if ZEUS demonstrates that ziltivekimab lowers inflammation through the IL-6 pathway and improves ASCVD outcomes, it would support NVO's cardiovascular adjacent asset positioning and benefit BIOA and LLY's NLRP3/inflammation pathway programs. Third, the report remains constructive on AMGN, ALNY, and MRK's upside opportunity in large cardiovascular product cycles.

Analysis framework

The report uses an event-driven clinical catalyst framework, combining trial statistical thresholds, scenario stock reactions, option-implied volatility, DCF/PoS sensitivity, and peer read-through analysis to assess the potential impact of HORIZON and ZEUS on the primary names and related companies.

Methodology notes

• Clinical catalyst analysisevent-driven clinical catalyst analysis

  Scenario assessment based on success criteria, failure risks, and stock reaction before and after clinical readouts.

  The report sets statistical and clinical significance thresholds for HORIZON and ZEUS and estimates the impact of positive, mixed, or failed outcomes on NVS, IONS, NVO, and related companies.

• Valuation approachDCF and P/E blend

  Using DCF, P/E, or a blend of both to set target prices for selected companies.

  For example, AMGN target pricing is based on DCF, while Novo Nordisk and Novartis use a 50% DCF and 50% P/E approach; for some pipeline assets, DCF sensitivity is observed through PoS changes.

• Probability adjustmentprobability of success sensitivity

  Assessing asset value changes by adjusting clinical success probability assumptions.

  The report uses PoS upward and downward adjustments for pelacarsen, ziltivekimab, obicetrapib, and CRSP LPA assets to estimate potential DCF or stock price impact.

• Market pricingoptions implied move analysis

  Using option-implied volatility to measure pre-event market expectations.

  The report notes that September options imply about +/-9.2% around HORIZON for Novartis and about +/-14.3% around ZEUS for Novo Nordisk.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• NVS/NOVN

  HORIZON lead sponsor, with pelacarsen commercial rights exposure; also holds IL-6 asset pacibekitug.

  Strengths

  If HORIZON succeeds, it could validate the Lp(a) class and support pelacarsen plus next-generation long-acting DII235; a positive ZEUS could also strengthen the IL-6 thesis.

  Weaknesses

  Current valuation is around 16x 2027E EPS, above the sector average of about 14x, and the report suggests multiple readouts may already be partially priced in.

  Comparison

  Compared with later-stage Lp(a) programs from AMGN and LLY, pelacarsen is a larger early-stage validation asset, but convenience of administration and persistent competition remain debated.

  Risks

  HORIZON failure, commercial screening and payer limits, imperfect follow-on catalysts, and Novartis valuation de-rating risk.

• IONS

  Pelacarsen milestone and royalty beneficiary.

  Strengths

  A positive HORIZON can re-rate PoS upward and expand peak-revenue scenarios, with the report estimating a highly positive outcome could deliver 10%-20% upside.

  Weaknesses

  Highly sensitive to pelacarsen readout; shares have already fallen materially after CARDIO-TTRansform.

  Comparison

  Compared with NVS, IONS is more of a royalty/milestone leverage exposure.

  Risks

  HORIZON failure could mean at least 10% downside; regulatory, reimbursement, commercialization, and competition risks remain elevated.

• NVO

  ZEUS lead sponsor, with ziltivekimab used to validate IL-6 inflammation reduction value in ASCVD.

  Strengths

  A successful outcome can anchor assets across obesity, diabetes, and cardiovascular-adjacent portfolios, reducing long-term concentration risk tied to semaglutide patent expiry.

  Weaknesses

  No prior direct cardiovascular efficacy record for ziltivekimab in this indication, making success threshold definition difficult.

  Comparison

  Compared with BIOA and LLY's NLRP3 pathway, NVO sits at an IL-6 downstream validation position.

  Risks

  ZEUS failure implies around 5% DCF downside; competitive obesity/GLP-1 data, manufacturing scale-up, and pricing pressure are also meaningful risks.

• AMGN/ARWR

  olpasiran is an Lp(a) siRNA program, with HORIZON results carrying read-through significance.

  Strengths

  olpasiran has quarterly dosing and has shown relatively strong Lp(a) lowering in prior data; if HORIZON validates the target, it could remove the potential downside risk around a major missed opportunity.

  Weaknesses

  AMGN's model does not yet incorporate olpasiran; phase 3 is expected to complete by 2028 and depends on event accrual.

  Comparison

  It may have stronger Lp(a) lowering magnitude than pelacarsen, but whether this translates to incremental clinical benefit still depends on baseline Lp(a) level and outcome data.

  Risks

  If HORIZON fails, the market may strip related value and apply valuation compression.

• BIOA

  ZEUS has read-through significance for BIOA oral NLRP3 inhibitor BGE-102 in the inflammation pathway.

  Strengths

  BGE-102 showed rapid and competitively strong hsCRP lowering in Ph1 MAD; a 15%-20% 3-point MACE benefit in ZEUS would support its cardiovascular risk pathway.

  Weaknesses

  The company still needs Phase 2 proof-of-concept data, and the primary endpoint is hsCRP lowering rather than hard outcomes.

  Comparison

  IL-6 is downstream of the NLRP3 inflammasome pathway; ZEUS could provide indirect mechanistic validation for NLRP3.

  Risks

  ZEUS failure could lead to 20%-30%+ downside in BIOA scenarios; even a non-significant but directional signal may still pressure the stock.

• NAMS

  Obicetrapib has Lp(a)-lowering effects and is affected by HORIZON target validation.

  Strengths

  Previous pooled Ph3 data show a median 45% Lp(a) placebo-adjusted reduction at best; a positive HORIZON can partly reduce PREVAIL CVOT risk narrative.

  Weaknesses

  Lp(a) lowering magnitude is weaker than dedicated Lp(a) drugs, and competitiveness still depends on pleiotropic and LDL-related contributions.

  Comparison

  Compared with PCSK9 agents with 15%-30% Lp(a) reduction, obicetrapib is higher, but below dedicated Lp(a) therapies at 80%-95%.

  Risks

  A negative HORIZON could weaken the Lp(a) narrative; PREVAIL trial failure, competition, pricing, and execution risks remain.

• CRSP

  CTX321 is a single-dose durable in vivo gene-editing Lp(a)-lowering asset.

  Strengths

  If HORIZON is positive, the report estimates a roughly 5% stock upside when LPA project PoS is raised from 15% to 50%; even a trend-only outcome can provide read-through.

  Weaknesses

  The program remains in IND/CTA-enabling stage and is far from commercialization, with peak-sales modeling extending to 2040.

  Comparison

  Gene editing may offer stronger and more durable Lp(a) reduction, but development and safety risk is higher than conventional drugs.

  Risks

  If HORIZON fails, lowering PoS to 0% could cause around 2.2% downside, plus potential non-fundamental de-rating.

• LLY

  Owns siRNA lepodisiran and oral muvalaplin; also holds NLRP3-related assets via Ventyx.

  Strengths

  Has positioning across both Lp(a) and inflammation cardiovascular risk pathways.

  Weaknesses

  Lp(a) assets are farther out on clinical timelines, with ACCLAIM-Lp(a) and MOVE-Lp(a) expected to complete around 2029 and 2031, respectively.

  Comparison

  Compared with NVS and NVO, LLY is more of a later-stage competitor and read-through beneficiary.

  Risks

  Long clinical timelines, changing competitive landscape, and mechanism validation failure risks.

Key data

• Stock reaction after CARDIO-TTRansformAZN -10%，IONS -33%，ALNY -11%，BBIO +6%Based on end-of-day prices before the July 8 announcement.
• HORIZON overall population significance thresholdApproximately 12% risk reductionGoldman Sachs' statistical analysis suggests this magnitude may be significant if achieved in Lp(a) ≥70mg/dL overall population.
• HORIZON high-risk subgroup significance thresholdApproximately 14% risk reductionHigh-risk subgroup defined as Lp(a) ≥90mg/dL.
• HORIZON trial sizen=8,323Monthly subcutaneous ASO pelacarsen versus placebo, with expanded MACE as endpoint.
• pelacarsen sales assumption$2bn peak sales, 60% PoSEmbedded in the NVS model.
• HORIZON scenario stock impactNVS +2%/-3%; IONS bull case about +10% to +20%, bear case at least -10%Based on positive or negative outcomes adjusted by pelacarsen PoS and peak-sales assumptions.
• ZEUS trial size and design6,200 ASCVD patients, 48 months, 1:1 randomization, quadruple-blindziltivekimab versus placebo.
• ZEUS clinical meaningfulness threshold15%-20% efficacy benefitThe report describes this as an industry reference range for cardiovascular drugs to be considered clinically meaningful.
• ZEUS statistical significance thresholdAround 12% MACE benefitGoldman Sachs estimates this magnitude may be sufficient for statistical significance.
• ziltivekimab model assumption40% PoS; 2037E risk-adjusted U.S. peak sales of DKK 10.5bn/$1.6bnIf PoS is raised to 100%, peak sales rise to approximately DKK 26.2bn/$4bn, implying about +7% DCF upside; at 0% PoS, roughly -5% downside.
• ZEUS scenario stock impactNVO +7%/-5%; BIOA +20% to +30% in significant and meaningful outcome scenarios, -20% to -30% on failureThe scenario table also includes approximately +1% for NVO and -15% to -20% for BIOA when results are non-significant but show a signal.

Impact & implications

The investment implication of the report is that 3Q26 cardiovascular catalysts may affect not only the directly involved companies but also risk appetite for the entire new-target category. HORIZON could determine whether the market is willing to assign a higher success probability and commercial expectations for Lp(a) lowering, while ZEUS could determine how strongly the inflammation pathway is validated in ASCVD and influence NVO's diversification narrative as well as valuations of related assets such as BIOA, LLY, and NOVN.

Risks

• HORIZON or ZEUS fail to achieve either statistical significance or clinically meaningful benefit, leading to a cooling of the target class.
• Even if HORIZON succeeds, commercialization may still be constrained by Lp(a) screening rates, payer coverage, dosing frequency, and competition from next-generation long-acting or oral therapies.
• Investor risk appetite has declined after CARDIO-TTRansform, and volatility around clinical readouts may exceed fundamental drivers before and after results.
• Novartis valuation may already reflect multiple key positive readouts, so any imperfect result could amplify downside.
• If ZEUS fails, the investment thesis that inflammation reduction and hsCRP can serve as MACE surrogate read-through could be weakened.
• Most related companies still face clinical, regulatory, reimbursement, competitive, patent, and commercial execution risks.

What to watch

• Whether HORIZON reaches statistical significance in the overall population with Lp(a) ≥70mg/dL and in the high-risk subgroup with Lp(a) ≥90mg/dL.
• Whether HORIZON shows a clear efficacy trend even if not significant, and how the magnitude of Lp(a) lowering maps to MACE benefit.
• Whether ZEUS reaches the approximately 12% statistical significance threshold and the 15%-20% industry clinical usefulness range.
• Commercialization guidance, payer discussions, and indication positioning from NVS, IONS, and NVO after readouts.
• Later 2H26/2027 catalysts such as AMGN olpasiran, LLY lepodisiran/muvalaplin, NAMS PREVAIL CVOT, and BIOA BGE-102.
• Deviations between option-implied volatility and actual stock reaction, especially event pricing of roughly +/-9.2% for NVS and +/-14.3% for NVO.